TransMedics Group Inc (TMDX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, TransMedics Group Inc (TMDX) has a cash flow conversion efficiency ratio of 0.073x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($34.51 Million) by net assets ($473.10 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
TransMedics Group Inc - Cash Flow Conversion Efficiency Trend (2006–2025)
This chart illustrates how TransMedics Group Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read how much debt does TransMedics Group Inc carry for a breakdown of total debt and financial obligations.
TransMedics Group Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of TransMedics Group Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Viohalco S.A
BR:VIO
|
0.050x |
|
SIASUN Robot Automation Co
SHE:300024
|
-0.019x |
|
Nuscale Power Corp
NYSE:SMR
|
-0.460x |
|
COSCO SHIPPING Specialized Carriers Co Ltd
SHG:600428
|
0.092x |
|
Essence Fastening Systems (Shanghai) Co. Ltd.
SHE:301005
|
-0.008x |
|
China Airlines Ltd
TW:2610
|
0.117x |
|
Willscot Mobile Mini Holdings Corp A
NASDAQ:WSC
|
0.186x |
|
Centerra Gold Inc
TO:CG
|
0.083x |
Annual Cash Flow Conversion Efficiency for TransMedics Group Inc (2006–2025)
The table below shows the annual cash flow conversion efficiency of TransMedics Group Inc from 2006 to 2025. For the full company profile with market capitalisation and key ratios, see TMDX company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $473.10 Million | $192.84 Million | 0.408x | +90.93% |
| 2024-12-31 | $228.60 Million | $48.80 Million | 0.213x | +324.83% |
| 2023-12-31 | $137.20 Million | $-13.03 Million | -0.095x | +61.17% |
| 2022-12-31 | $187.38 Million | $-45.82 Million | -0.245x | +42.52% |
| 2021-12-31 | $67.85 Million | $-28.86 Million | -0.425x | -46.02% |
| 2020-12-31 | $103.89 Million | $-30.27 Million | -0.291x | +50.69% |
| 2019-12-31 | $54.65 Million | $-32.29 Million | -0.591x | -110.97% |
| 2018-12-31 | $-4.83 Million | $-25.98 Million | 5.385x | +3833.79% |
| 2017-12-31 | $-168.72 Million | $-23.10 Million | 0.137x | +122.03% |
| 2016-12-31 | $38.79 Million | $-24.11 Million | -0.622x | +66.36% |
| 2006-12-31 | $8.80 Million | $-16.27 Million | -1.847x | -- |
About TransMedics Group Inc
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic con… Read more